Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News

ETF Overview

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Key Stats

• Today's Range: $9.82 to $10.18
• 50-Day Range: $9.46 to $10.33
• 52-Week Range: $9.40 to $12.53
• Volume: 91,983 shs
• Average Volume: 66,491 shs
• Market Capitalization: $68.52 million
• Assets Under Management: $65.71 million
• Dividend Yield: 0.00%
• Net Expense Ratio: 0.50%
• Aggregate Rating: Moderate Buy

GNOM ETF - Frequently Asked Questions

How have GNOM shares performed this year?

Global X Genomics & Biotechnology ETF's stock was trading at $9.71 at the start of the year. Since then, GNOM shares have increased by 1.2% and is now trading at $9.83.
View the best growth stocks for 2025 here.

Who are Global X Genomics & Biotechnology ETF's major shareholders?

Top institutional shareholders of Global X Genomics & Biotechnology ETF include One Capital Management LLC (10.33%), Raymond James Financial Inc. (4.39%), Raymond James Financial Inc. (4.39%) and Portland Global Advisors LLC (3.86%).

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL).

Fund Details

• Issuer: Global X
• Fund Name: Global X Genomics & Biotechnology ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:GNOM
• Inception Date: 4/5/2019
• Fund Manager: Chang Kim, James Ong, Nam To, Wayne Xie
• Web: www.completegenomics.com
• Phone: +1-650-9432800

Fund Focus

• Asset Class: Equity
• Benchmark: Solactive Genomics Index
• Category: Strategy
• Focus: Theme
• Development Level: Blended Development
• Region: Global
• Number of Holdings: 42

Fund Statistics

• Assets Under Management: $65.71 million
• Average Daily Volume: $0.00
• Discount/Premium: 0.02%

Administrator, Advisor and Custodian

• Administrator: Global X Management Company LLC
• Advisor: Global X Management Company LLC
• Custodian: Brown Brothers Harriman & Co.
• Distributor: SEI Investments Distribution Co.
• Transfer Agent: Brown Brothers Harriman & Co.
• Trustee: N/A
• Lead Market Maker: Susquehanna

Options

• Optionable: Optionable
• Options Volume: 2
• Put Options: 30
• Call Options: 2
• Short Interest: 12,700 shs

Miscellaneous

• Outstanding Shares: 6,970,000
• Beta: 1.03
• Creation Unit: 50,000
• Creation Fee: $500.00